

**Reference Number:** FOI202223/256  
**From:** Private Individual  
**Date:** 24 August 2022  
**Subject:** Medicines used in treatment of Melanoma patients

- Q1 In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:
- Bevacizumab (Avastin)
  - Dacarbazine (DTIC)
  - Trametinib (Mekinist)
  - Dabrafenib (Tafinlar)
  - Ipilimumab (Yervoy)
  - Vemurafenib (Zelboraf)
  - Nivolumab (Opdivo)
  - Nivolumab + Ipilimumab (Opdivo + Yervoy)
  - Pembrolizumab (Keytruda) • Vemurafenib + cobimetinib (Zelboraf + Cotellic)
  - Dabrafenib + Trametinib (Tafinlar + Mekinist) • Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
  - Other active systemic anti-cancer therapy [please state]
  - Palliative care only

A1 [Information not held – The Trust has treated zero melanoma patients in this period](#)

- Q2 In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:
- Ipilimumab
  - Ipilimumab AND Nivolumab
  - Nivolumab
  - Pembrolizumab
  - Dabrafenib AND Trametinib
  - Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
  - Other active systemic anti-cancer therapy
  - Palliative care only

A2 [Information not held – The Trust has treated zero metastatic melanoma patients in this period](#)